Lung Cancer Risk, Occupational Exposure, and the Debrisoquine Metabolic Phenotype

Cancer Research

Volumn 49, Issue 13, 1989, Pages 3675-3679

  Caporaso, Neil ^a,d   Hayes, Richard B ^a   Dosemeci, Mustafa ^a   Hoover, Robert ^a   Ayesh, Riad ^b   Idle, Jeffrey ^b,e   Hetzel, Martin ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c WHITTINGTON HOSPITAL   (United Kingdom)

^d Environ Epidemiol Br DCEG N   (United States)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; CARCINOGEN; DEBRISOQUINE; POLYCYCLIC AROMATIC HYDROCARBON;

ADULT; AGED; CARCINOGENESIS; DRUG METABOLISM; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SMOKING;

ASBESTOS; DEBRISOQUIN; FEMALE; HUMAN; ISOQUINOLINES; LUNG DISEASES, OBSTRUCTIVE; LUNG NEOPLASMS; MALE; OCCUPATIONAL DISEASES; OXIDATION-REDUCTION; POLYCYCLIC HYDROCARBONS; RISK FACTORS; SMOKING; SUPPORT, NON-U.S. GOV'T;

EID: 0024383540     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Ayesh, R., Idle, J. R., Ritchie, J. C., Crothers, M. J. and Hetzel, M. R. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature (Lond.), 312: 169-170, 1984.
2. Caporaso, N., Hoover, R., Aisner, S., Resau, J., Trump, B., Issaq, H., Muschik, G., and Harris, C. C. Debrisoquine metabolic phenotype and the risk of lung cancer (Abstract 336). Proc. Soc. Clin. Oncol., 8:1988.
3. Evans, D. A. P., Mahgoub, A., Sloan, T. P., Idle, J. R., and Smith, R. L. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J. Med. Genet., 17: 102-105,1980.
4. Mahgoub, A., Idle, J. R., and Smith, R. L. A population and familial study of the defective alicyclic hydroxylation of debrisoquine among Egyptians. Xenobiotica, 9: 51-56, 1979.
5. Eichelbaum, M., Baur, M. P., Dengler, H. J., Osikowska-Evers, B. O., Tieves, G., Zekorn, C., and Rittner, C. Chromosomal assignment of human chromosome P-450 (debrisoquine/sparteine type) to chromosome 22. Br. J. Clin. Pharmacol., 23:455-458, 1987.
6. Dayer, P., Kronbach, T., Eichelbaum, M., and Meyer, U. Enzymatic basis of the debrisoquine/sparteine type genetic polymorphism of drug oxidation. Biochem. Pharmacol., 36:4145-4152, 1987.
7. Gonzalez, F. J., Skoda, R. C., Kimura, S., Umeno, M., Zanger, U. M., Nebert, D. W., Gelboin, H. V., Hardwick, J. P., and Meyer, U. A. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature (Lond.), 331:442-446, 1988.
8. Skoda, R. C., Gonzalez, F. J., Demierre, A., and Meyer, U. A. Two mutant alleles of the human cytochrome P-450dbl gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc. Natl. Acad. Sci. USA, 85:5240-5243, 1988.
9. BMDPLR—Stepwise Logistic Regression, BMDP Statistical Software Inc., 1964 Westwood Blvd., Suite 202. Copyright Regents of California, 1983.
10. Breslow, N. E., and Day, N. E. Statistical Methods in Cancer Research, Volume 1-The Analysis of Case-Control Studies, Lyon, (IARC Scientific Publications No. 32), pp. 192-246,1980.
11. Cole, P., and MacMahon, B. Attributable risk percent in case-control studies. Br. J. Prev. Soc. Med., 25: 242-244,1971.
12. Rothman, K. J., Modern Epidemiology, pp. 311-326. Boston/Toronto: Little Brown and Company, 1986.
13. Schlesselman, J. J. Case-control Studies, pp. 65-68. New York: Oxford University Press, 1982.
14. Steiner, E., Iselius, L., Alvan, G., Lindsten, J., and Sjôqvist, F. A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin. Clin. Pharmacol. Ther., 38:394-400, 1985.
15. Steiner, E., Bertilsson, L., Sawe, J., Bertling, I., and Sjôqvist, F. Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. Clin. Pharm. Ther., 44: 431-435, 1988.
16. Peart, G. F., Boutagy, J., and Shenfield, G. M. Debrisoquine oxidation in an Australian population. Br. J. Pharmacol. 21:465-471,1986.
17. Nakamura, K., Goto, F., Ray, W. A., McAllister, C. B., Jacqz, E., Wilkinson, G. R., and Branch, R. A. Interethnic differences in genetic polymorphism of debrisoquine hydroxyation between Japanese and Caucasian populations. Clin. Pharm. Ther., 38:402-408, 1985.
18. Ayesh, R., and Idle, J. R. Evaluation of drug oxidation phenotypes in the biochemical epidemiology of lung cancer risk. In: A. R. Boobis, J. Caldwell, F. DeMatteis, and C. R. Elcombe (eds.) Proceedings of the 6th International Symposium Microsomes and Drug Oxidations, pp. 340-346. London: Taylor and Francis, 1985.
19. Harris, C. C., Vahakangas, K., Autrup, H., Trivers, G. E., Shamsuddin, A. K. M., Trump, B. F., Boman, B. M., and Mann, D. L. Biochemical and molecular epidemiology of cancer risk. In: The Pathologist and the Environment, pp. 140-167. International Academy of Pathology, Monograph No. 26, Baltimore, MD: Williams & Wilkins, 1985.
20. Vessell, E. S., and Penno, M. B. Assessment of methods to identify sources of interindividual pharmacokinetic variations. Clin. Pharmacokinet., 8:378-409, 1983.
21. Sloan, T. P., Mahgoub, A., Lancaster, R., Idle, J. R., and Smith, R. L. Polymorphism of carbon oxidation of drugs and clinical implications. Br. Med. J., 2:655-657, 1978.
22. Nebert, D. W. Genes encoding drug-metabolizing enzymes: possible role in human disease. In: A. D. Woodhead, M-A. Bender, and R. C. Leonard (eds.), Phenotypic Variation in Populations: Relevance to Risk Assessment. New York: Plenum Press, 1988.
23. Idle, J. R., and Smith, R. L. Polymorphisms of oxidation at carbon centers and their clinical significance. Drug Metabol. Rev., 9: 301-317, 1979.